Publikationen

Publikationsliste Rupert Bartsch

Publikationen in Journalen mit Peer Review

1. Tendl-Schulz KA, Rössler F, Wimmer P, Heber UM, Mittlböck M, Kozakowski N, Pinker K, Bartsch R, Dubsky P, Fitzal F, Filipits M, Eckel FC, Langthaler EM, Steger G, Gnant M, Singer CF, Helbich TH, Bago-Horvath Z. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. Virchows Arch 2020;[Epub ahead of print].
2. Fuereder T, Gunsilius E, Bartsch R, Hilbe W; editors of memo. Circumnavigating the challenges of COVID-19 in oncology. Memo 2020;7:1-4.
3. Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M; Austrian Breast & Colorectal Cancer Study Group. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). Eur J Cancer 2020;132:43-52.
4. Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. Breast 2020;50:64-70.
5. Huober J, Bartsch R, Marmé F, Pagani O, Thomssen C. Luminal Metastatic Breast Cancer. Breast Care (Basel) 2019;14:99-101.
6. Obermeier HL, Riedl J, Ay C, Koder S, Quehenberger P, Bartsch R, Kaider A, Zielinski CC, Pabinger I. The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost 2019;3:503-514.
7. Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg 2019;269:1163-1169.
8. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol 2019;20:371-382.
9. Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R. Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. Clin Cancer Res 2019;25:2737-2744.
10. Bartsch R, Bergen E. ASCO 2018: highlights in HER2-positive metastatic breast cancer. Memo 2018;11:280-283.
11. Füreder LM, Widhalm G, Gatterbauer B, Dieckmann K, Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff AS. Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. Clin Exp Metastasis 2018;35:727-738.
12. Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). BMC Cancer 2018;18:1074.
13. Tahmassebi A, Wengert GJ, Helbich TH, Bago-Horvath Z, Alaei S, Bartsch R, Dubsky P, Baltzer P, Clauser P, Kapetas P, Morris EA, Meyer-Baese A, Pinker K. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients. Invest Radiol 2019;54:110-117.
14. Bartsch R, Bergen E. SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy. Memo 2018;11:204-207.
15. Bartsch R, Bergen E, Galid A. Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. Memo 2018;11:199-203.
16. Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open 2018;3:e000368.
17. Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg 2018;[Epub ahaead of print].
18. Kiesewetter B, Dediu M, Bartsch R. ESMO 2017-my personal highlights. Memo 2018;11:77-79.
19. Bergen ES, Bartsch R. My burning issues in the neoadjuvant treatment for breast cancer. Memo 2018;11(1):27-30.
20. Kowalczyk L, Bartsch R, Singer CF, Farr A. Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. Breast Care (Basel) 2017;12:401-408.
21. Bartsch R. Ribociclib: a valuable addition to treatment options in breast cancer? ESMO Open 2017;2:e000246.
22. Bartsch R, Bergen E. ASCO 2017: highlights in breast cancer. Memo. 2017;10:228-232.
23. Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E. Biosimilars in the Treatment of Breast Cancer. Breast Care (Basel) 2017;12:192-194.
24. Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. Eur J Cancer Care (Engl) 2017;[Epub ahead of print].
25. Dediu M, Gerger A, Zojer N, Bartsch R. My personal highlights of ESMO 2016. MEMO 2017;10:46-47.
26. Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clin Cancer Res 2017; 23:3676-3683.
27. Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M. Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. Neuro Oncol 2017; 19:1255-1262.
28. Pluschnig U, Haslik W, Bartsch R, Mader RM. Extravasation emergencies: state-of-the-art management and progress in clinical research. MEMO 2016;9:226-230.
29. Bartsch R, Bergen E. ASCO 2016: highlights in breast cancer. MEMO 2016;9:211-214.
30. Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. Eur Radiol 2017; 27:3167-3173.
31. Bartsch R, de Azambuja E. I-SPY 2: optimising cancer drug development in the 21st century. ESMO Open 2016;1:e000113.
32. Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066.
33. Marhold M, Bartsch R, Zielinski C. Recent developments and translational aspects in targeted therapy for metastatic breast cancer. ESMO Open 2016;1:e000036.
34. Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open 2016;1:e000024.
35. Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol 2016;130:19-29.
36. Minarikova L, Bogner W, Pinker K, Valkovič L, Zaric O, Bago-Horvath Z, Bartsch R, Helbich TH, Trattnig S, Gruber S. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer. Eur Radiol 2017;27:1901-1911.
37. Spick C, Bickel H, Pinker K, Bernathova M, Kapetas P, Woitek R, Clauser P, Polanec SH, Rudas M, Bartsch R, Helbich TH, Baltzer PA. Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy. NMR Biomed 2016;29:1445-1453.
38. Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med 2016;5:2350-2358.
39. Gnant M, Steger GG, Bartsch R. Pathological complete remission and long-term outcome-what do we know in 2016? Lancet Oncol 2016;17:693-694.
40. Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat 2016;157:91-99.
41. Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H, Dressler A, Gnant M, Zielinski C, Bartsch R. A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. Clin J Oncol Nurs 2016;20:175-180.
42. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 2015;5:e1057388.
43. Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF, Petruzelka L, Melichar B, Knittelfelder R, Brodowicz T, Zielinski C. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.BMC Cancer 2016;16:121.
44. Steger GG, Gnant M, Bartsch R. Palbociclib for the treatment of postmenopausal breast cancer - an update. Expert Opin Pharmacother 2016;17:255-263.
45. Bartsch R, Gnant M, Steger GG. Bevacizumab: no comeback in early breast cancer? Lancet Oncol 2015;16:1001-1003.
46. Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis 2015;32:729-737.
47. Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. Clin Breast Cancer 2015;15:505-511.
48. Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwetter R, Gnant M. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer 2015;112:1405-1410.
49. Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA Jr. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Breast 2015;24:513-523.
50. Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R. Taxanes plus trastuzumab compared to oral vinorelbine plus trastuzumab in HER2-overexpressing metastatic breast cancer. Breast Care (Basel) 2014;9:344-3448.
51. Haslik W, Hacker S, Felberbauer FX, Thallinger C, Bartsch R, Kornauth C, Deutschmann C, Mader RM. Port-a-Cath® extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy. Eur J Surg Oncol 2015;41:378-385.
52. Pluschnig U, Haslik W, Bayer G, Soleiman A, Bartsch R, Lamm W, Steger GG, Zielinski CC, Mader RM. Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. Support Care Cancer 2015;23:1741-1748.
53. Bergen ES, Berghoff AS, Rudas M, Preusser M, Bartsch R. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. Anticancer Drugs 2015; 26:579-581.
54. Gnant M, Steger GG, Bartsch R. CDK4/6 inhibitors in luminal breast cancer. Lancet Oncol 2015;16:2-3.
55. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R; on behalf of the Austrian Breast and Colorectal Cancer Study Group Vienna Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015;26:313-320.
56. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Höller C, Preusser M. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2015;66:289-99.
57. Berghoff AS, Bartsch R, Wöhrer A, Streubel B, Birner P, Kros JM, Brastianos PK, von Deimling A, Preusser M. Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathol 2014;128:879-891.
58. Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Pichler J, Hutterer M, Melchardt T, Bartsch R, Zielinski CC, Birner P, Preusser M. Differential role of angiogenesis and tumor cell proliferation in brain metastases according to primary tumor type: analysis of 639 cases. Neuropathol Appl Neurobiol 2015;41:e41-55.
59. Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M, Goodman SL, Birner P, Preusser M. αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clin Exp Metastasis 2014;31:841-851.
60. Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast 2014;23:637-643.
61. Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer. Br J Cancer 2014;111:837-842.
62. Pinker K, Bogner W, Baltzer P, Karanikas G, Magometschnigg H, Brader P, Gruber S, Bickel H, Dubsky P, Bago-Horvath Z, Bartsch R, Weber M, Trattnig S, Helbich TH. Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study. Clin Cancer Res 2014;20:3540-3539.
63. Lück HJ, Untch M, Jackisch C, Zielinski C, Bartsch R. Optimal Sequencing of Anti-HER2 Therapy. Breast Care (Basel) 2014;9:138-140.
64. Berghoff AS, Sax C, Klein M, Furtner J, Dieckmann K, Gatterbauer B, Widhalm G, Rudas M, Zielinski CC, Bartsch R, Preusser M. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report. Breast Care (Basel) 2014;9:134-136.
65. Gnant M, Bartsch R, Steger GG. HER2-positive breast cancer: a new piece of the puzzle. Lancet Oncol 2014;15:668-669.
66. Pinker K, Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, Trattnig S, Weber M, Dubsky P, Bago-Horvath Z, Bartsch R, Helbich TH. Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging. Invest Radiol 2014;49:421-430.
67. Birner P, Bartsch R, Schreiber M, Dubsky P, Kenner L. New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target? Future Oncol 2014;10:333-336.
68. Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol 2014;73:771-778.
69. Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer Res 2014;34:227-233.
70. Haslik W, Pluschnig U, Steger GG, Zielinski CC, Schrögendorfer KF, Nedomansky J, Bartsch R, Mader RM. Indocyanine green video angiography predicts outcome of extravasation injuries. PLoS One 2014;9:e103649.
71. Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA). Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Ann Oncol 2014;25:773-780.
72. Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; Austrian Breast and Colorectal Study Group (ABCSG). Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol 2014;25:366-371.
73. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014;25:339-345.
74. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med 2013;11:307.
75. Moshammer MI, Kalipciyan M, Bartsch R, Steger GG, Sedivy R, Mader RM. Exosomal microRNA transfer varies with specific microRNAs functional in colorectal cancer and cellular differentiation. Int J Clin Pharmacol Ther 2014;52:87-88.
76. Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro Oncol 2013;15:1664-1672.
77. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 2014;116:205-206.
78. Steger GG, Bartsch R. ASCO 2013: News in early stage and advanced breast cancer. Magazine of European Medical Oncology 2013; 6:227-232.
79. Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R, Dimopoulos MA. Challenges in managing breast cancer during pregnancy. J Thorac Dis 2013;5(Suppl.1):S62-67.
80. Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M, Bartsch R, Dimopoulos MA, Psaltopoulou T. Pertuzumab in breast cancer: a systematic review. Clin Breast Cancer 2013;13:315-324.
81. Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Papadimitriou CA, Dimopoulos MA, Filipits M, Bartsch R. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas 2013;42:760-773.
82. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA, Bartsch R. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 2013;108:2259-2263.
83. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 2013;139:13-22.
84. Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, Dimopoulos MA, Filipits M. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013;108:1100-1105.
85. Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest 2013;43:286-291.
86. Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer. Breast J 2013;19:149-155.
87. Zagouri F, Sergentanis TN, Chrysikos D, Bartsch R. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol 2013;121(2 Pt 1):337-343.
88. Körber MI, Klingenbrunner S, Bartsch R, Steger GG, Mader RM. NF-κB addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model. Int J Clin Pharmacol Ther 2013;51:35-37.
89. Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R. Fulvestrant and male breast cancer: a case series. Ann Oncol 2013;24:265-266.
90. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:349-357.
91. Bartsch R, Berghoff AS, Preusser M. Optimal management of brain metastases from breast cancer. Issues and considerations. CNS Drugs 2013;27:121-134.
92. Bartsch R, Preusser M. Primary systemic treatment of breast-cancer brain metastases. Lancet Oncol 2013;14:8-9.
93. Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, Magerle M, Dieckmann K, Marosi C, Birner P, Widhalm G, Steger GG, Zielinski CC, Bartsch R, Preusser M. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer 2012;107:1454-1458.
94. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol 2012;127:662-672.
95. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 2012;83:234-238.
96. Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R. Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. Oncologist 2012;17:e13-17.
97. Dubsky P, Bartsch R. Bisphosphonates in early breast cancer. Lancet Oncol 2012;13:660-661.
98. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol 2012;126:291-303.
99. Hubalek M, Bartsch R, Gnant M, Kapp KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch J, Zeimet AG, Marth C. Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. Geburtshilfe Frauenheilkd 2012;72:293-298.
100. Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 2012;48:1932-1938.
101. Steger GG, Bartsch R. Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer. Breast Care (Basel) 2011;6:427-433.
102. Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2012;30:722-728.
103. Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012;106:440-446.
104. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-222.
105. Bartsch R, Dubsky PC, Loibl S, Steger G. Opinions on the ASCO 2011 Annual Meeting. Breast Care (Basel) 2011;6:315-319.
106. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012;106:25-31.
107. Steger GG, Bartsch R. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 2011;3:233-243.
108. Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer 2011;11:373.
109. Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. Ann Surg Oncol 2012;19:519-526.
110. Gampenrieder SP, Bartsch R, Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC, Steger GG. Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care (Basel) 2010;5:158-162.
111. Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer 2010;103:1201-1208.
112. Fitzal F, Riedl O, Mittlböck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M. Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. Breast Cancer Res Treat 2011;127:121-128.
113. Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast cancer. Wien Med Wochenschr 2010;160:174-181.
114. Bartsch R, Ziebermayr R. ASCO 2010: update on metastatic breast cancer. MEMO 2010;3:159-62.
115. Kierner KA, Gartner V, Bartsch R, Hladschik-Kermer B, Gruber A, Hassler M, Watzke HH. Attitudes towards palliative care in primary metastatic cancer: a survey among oncologists. Wien Klin Wochenschr 2010;122:45-49.
116. Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, Bartsch R, Steger G, Pehamberger H, Scheiner O, Zielinski CC. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2010;119:673-683.
117. Fromm-Haidenberger S, Pohl G, Widder J, Kren G, Fitzal F, Bartsch R, de Vries J, Zielinski C, Pötter R. Vienna international summer school on experimental and clinical oncology for medical students: an Austrian cancer education project. J Cancer Educ 2010;25:51-54.
118. Bartsch R, Steger GG, Gnant M, Ziebermayr R. Breast Cancer: Rank Ligand Inhibition. Breast Care (Basel) 2010;5:320-325.
119. Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG. Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 2009;9:367.
120. Tomova A, Bartsch R, Brodowicz T, Tzekova V, Timcheva C, Wiltschke C, Gerges DA, Pawlega J, Spanik S, Inbar M, Zielinski CC. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 2010;119:169-176.
121. Bartsch R, Steger GG. Role of denosumab in breast cancer. Expert Opin Biol Ther 2009;9:1225-1233.
122. Bartsch R, Steger GG. The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools. Breast Care (Basel). 2009;4:167-176.
123. Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat 2009;115:373-380.
124. Fromm S, Bartsch R, Rudas M, de Vries A, Wenzel C, Steger GG, Zielinski CC, Poetter R, Dieckmann K. Factors influencing the time to development of brain metastases in breast cancer. Breast 2008;17:512-516.
125. Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res 2008;14:2082-2087.
126. Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2008;62:903-910.
127. Bartsch R, Steger GG. Adjuvant chemotherapy in breast cancer. MEMO 2008;1:91-98.
128. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853-3858.
129. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Mader RM, Gnant M, Jakesz R, Rudas M, Zielinski CC, Steger GG. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 2007;13(15 Pt 1):4435-4439.
130. Bartsch R, Steger GG, Forstner B, Wenzel C, Pluschnig U, Rizovski B, Altorjai G, Zielinski CC, Mader RM. Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. BMC Clin Pharmacol 2007;7:7.
131. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311-317.
132. Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs 2007;21:69-77.
133. Bartsch R, Wenzel C, Steger GG. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 2007;1:19-31.
134. Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007;104:109-114.
135. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Bachleitner-Hoffmann T, Locker GJ, Rudas M, Mader R, Zielinski CC, Steger GG. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007;102:375-381.
136. Bartsch R. Comment on the letter to the editor „Hormone receptor status as an independent variable affecting the survival of advanced breast cancer patients with brain metastases“ (Hakan Harputluoglu et al.). Radiother Oncol 2007;2:375.
137. Bartsch R, Fromm S, Rudas M, Wenzel C, Harbauer S, Roessler K, Kitz K, Steger GG, Weitmann HD, Poetter R, Zielinski CC, Dieckmann K. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol 2006;80:313-317.
138. Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res 2006;26:3187-3190.
139. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altorjai G, Locker GJ, Mader R, Zielinski CC, Steger GG. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 2006;6:81.
140. Bartsch R, Wenzel C, Hussian D, Pluschnig U, Sevelda U, Koestler W, Altorjai G, Locker GJ, Mader R, Zielinski CC, Steger GG. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006;6:63.
141. Bartsch R, Weitmann HD, Pennwieser W, Wenzel C, Muschitz S, Baldass M, Hassler M, Marosi C, Rössler K, Pötter R, Dieckmann K. Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wien Klin Wochenschr 2005;117:821-826.
142. Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:8442-8446.
143. Wöhrer S, Bartsch R, Hejna M, Drach J, Raderer M. Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy. Scand J Gastroenterol 2005;40:1222-1225.
144. Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Gnant MF, Jakesz R, Zielinski CC. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005;41:2655-2661.
145. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Mader R, Zielinski CC, Steger GG. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol 2006;57:554-558.
146. Wenzel C, Locker GJ, Bartsch R, Pluschnig U, Hussian D, Zielinski CC, Rudas M, Gnant MF, Jakesz R, Steger GG. Preoperative second-line chemotherapy induces objective responses in primary breast cancer. Wien Klin Wochenschr 2005;117:48-52.
147. Bartsch R, Wenzel C, Sevelda U, Hussian D, Pluschnig U, Locker GJ, Mader R, Zielinski CC, Steger GG. Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience. Anticancer Drugs 2005l;16:617-620.
148. Wenzel C, Bartsch R, Locker GJ, Hussian D, Pluschnig U, Sevelda U, Gnant MF, Jakesz R, Zielinski CC, Steger GG. Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. Anticancer Drugs 2005;16:441-445.
149. Wöhrer S, Streubel B, Bartsch R, Chott A, Raderer M. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 2004;10:7179-7181.
150. Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M, Gnant MF, Jakesz R, Zielinkski CC, Steger GG. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004;130:400-404.
151. Wenzel C, Bartsch R, Hussian D, Pluschnig U, Locker GJ, Sevelda U, Zielinski CC, Steger GG. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Support Care Cancer 2004;12:678-681.
152. Wenzel C, Locker GJ, Bartsch R, Pluschnig U, Mader R, Hussian D, Kramer G, Marberger M, Lintner C, Rauchenwald M, Zielinski CC, Steger GG. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs 2003;14:779-784.
153. Steger GG, Wenzel C, Bartsch R, Rudas M, Gnant M, Zielinski CC, Jakesz R. Preliminary results of a pilot-trial with trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary, operable breast cancer. Breast 2003;12(Suppl.1):S29-40.
     

Buchbeiträge

1. Bartsch R, Steger GG. Denosumab – das Molekül: Erster klinischer Einsatz (German). In: Gnant M, Hadji P (Eds.). Osteo-Onkologie – RANKL-Inhibition beim Mammakarzinom, pp 50-55. Uni-Med Verlag 2009.
2. Bartsch R, Steger G. Mammakarzinom (German). In: Marian B (Ed.). Krankheit, Krankheitsursachen und -bilder, 5th Edition, pp 360-384. Facultas. wuv 2010.
3. Bartsch R, Steger GG. Trastuzumab as adjuvant treatment for early stage Her2-positive breast cancer. In: Sibilia M, Zielinski CC, Bartsch R, Grunt T (Eds.). Milestones in Drug Therapy: Drugs for HER-2-positive Breast Cancer, pp 33-50. Springer Basel 2011.
4. De Vries C, Bartsch R. Die neoadjuvante Therapie des Mammakarzinoms (German). In: Kandioler D (Ed.). Manual der chirurgische Krebstherapie, pp 98-101. Krause und Pachernegg 2011.
5. Bartsch R, Steger GG. Guidelines zur palliative systemischen Therapie (German). In: Kandioler D (Ed.). Manual der chirurgische Krebstherapie, pp 127-139. Krause und Pachernegg 2011.